Results 231 to 240 of about 875,619 (302)

RETRACTED: Wee et al. Triaging Medical Referrals Based on Clinical Prioritisation Criteria Using Machine Learning Techniques. <i>Int. J. Environ. Res. Public Health</i> 2022, <i>19</i>, 7384. [PDF]

Int J Environ Res Public Health
Wee CK, Zhou X, Sun R, Gururajan R, Tao X, Li Y, Wee N.   +6 more
europepmc   +1 more source

Cracking the Code: A Practical Guide to Publishing in the ACG Case Reports Journal. [PDF]

ACG Case Rep J
Zaver HB, Abbas D, Harne PS.
europepmc   +1 more source

Correction: Hosseinikha et al. Nanomaterials for the Diagnosis and Treatment of Inflammatory Arthritis. <i>Int. J. Mol. Sci.</i> 2021, <i>22</i>, 3092. [PDF]

Int J Mol Sci
Hosseinikhah SM, Barani M, Rahdar A, Madry H, Arshad R, Mohammadzadeh V, Cucchiarini M.   +6 more
europepmc   +1 more source

A companion to the preclinical common data elements for rigor, reproducibility and transparency in basic and translational epilepsy research. A report of the TASK3‐WG1A: Pharmacology Working Group of the ILAE/AES Joint Translational Task Force

Epilepsia Open, EarlyView.
Abstract Rigorous and transparent procedures in preclinical epilepsy research studies are important to permit assessing the reproducibility of their findings and derisk their translation into the clinic. The General Pharmacology Working Group of the ILAE/AES Task Force (TASK3‐WG1A) developed common data elements (CDEs) addressing rigor and transparency
Brian D. Klein, Lauren Harte‐Hargrove, Wenzhu Mowrey, Aristea S. Galanopoulou, Cameron S. Metcalf, Lisa Coles, Patrick A. Forcelli, Anna‐Maria Katsarou, Rudiger Koehling, Karine Leclercq, Heidrun Potschka, TASK3‐WG1A working group   +11 more
wiley   +1 more source

A Chapter Closes at <i>Environmental Health Perspectives</i>. [PDF]

Environ Health Perspect
Kaufman JD.
europepmc   +1 more source

Precision therapies for genetic epilepsies in 2025: Promises and pitfalls

Epilepsia Open, EarlyView.
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang, Emilio Perucca, Samuel F. Berkovic, Piero Perucca   +3 more
wiley   +1 more source

Editorial board [PDF]

Macedonian Veterinary Review, 2010
Macedonian Veterinary Review
doaj  

Message from the New Editor-in-Chief: Continuity and Change, Impact and Visibility. [PDF]

Indian J Crit Care Med
Divatia JV.
europepmc   +1 more source

Inequalities in access to industry‐funded interventional phase I–IV drug trials in epilepsy

Epilepsia Open, EarlyView.
Abstract Objective Clinical trials on drug safety and efficacy are understood to be valid for all humans, but are not equally distributed worldwide. We aimed to analyze the global distribution of clinical drug trials (phase I–IV) in epilepsy and its correlation with key demographical and epidemiological factors.
Robert Hoepner, Alejandro Xavier León Betancourt, Stefanie Marti, Andrea Seiler   +3 more
wiley   +1 more source

Editorial board [PDF]

Macedonian Veterinary Review, 2011
Macedonian Veterinary Review
doaj